Candriam SCA’s Morphic Holding, Inc. Common Stock MORF Stock Holding History

Candriam SCA’s Portfolio MORF Stock Details MORF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-214,154	Closed	-$7.3M	–	721
2024 Q2	$7.3M	Sell	214,154 -35,779	-14%	-$1.06M	0.04%	290
2024 Q1	$8.8M	Hold	249,933	–	–	0.06%	270
2023 Q4	$7.22M	Hold	249,933	–	–	0.05%	296
2023 Q3	$5.73M	Hold	249,933	–	–	0.04%	295
2023 Q2	$14.3M	Sell	249,933 -40,000	-14%	-$2.09M	0.1%	201
2023 Q1	$18.5M	Sell	289,933 -55,000	-16%	-$2.03M	0.13%	175
2022 Q4	$9.23M	Hold	344,933	–	–	0.06%	288
2022 Q3	$9.76M	Hold	344,933	–	–	0.07%	279
2022 Q2	$7.49M	Buy	344,933 +160,537	+87%	+$4.48M	0.06%	270
2022 Q1	$7.4M	Buy	+184,396	New	+$7.72M	0.05%	294

Other funds holding MORF

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Hoey Investments Coatesville, Pennsylvania $774M AUM 27.34% 1-Year Est. Return

Candriam SCA's MORF Position: Q3 2024 in Review

Candriam SCA sold out of Morphic Holding, Inc. Common Stock (MORF) in Q3 2024, closing a stake of 214,154 shares — an estimated $7.3M sold.

Candriam SCA first reported a position in MORF in Q1 2022 and held it in 10 quarters. The position peaked at $18.5M in Q1 2023. 2 funds tracked by Wall St. Rank hold MORF as of Q3 2024.

Candriam SCA reported no remaining Morphic Holding, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Candriam SCA sold 214,154 Morphic Holding, Inc. Common Stock shares in Q3 2024, an estimated $7.3M.
Candriam SCA first reported a position in Morphic Holding, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
Candriam SCA's Morphic Holding, Inc. Common Stock position peaked at $18.5M in Q1 2023.
2 funds tracked by Wall St. Rank held Morphic Holding, Inc. Common Stock as of Q3 2024.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.